Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Everolimus (Afinitor) tablets Clear all
Completed Phase 1Phase 2 Interventional Results available

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

NCT01070316
View directory record Official record
Conditions
Epilepsy, Tuberous Sclerosis Complex
Interventions
Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

NCT02991807
View directory record Official record
Conditions
PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Interventions
RAD001, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 28, 2026, 4:30 PM EDT
Withdrawn Phase 2 Interventional

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

NCT01997255
View directory record Official record
Conditions
Sturge Weber Syndrome
Interventions
Everolimus
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

NCT01482156
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
Interventions
RAD001 + BEZ235
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Fayetteville, Arkansas • St Louis, Missouri • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy

NCT00419159
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 28, 2026, 4:30 PM EDT
Recruiting Phase 2Phase 3 Interventional

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions
Zanzalintinib, Everolimus
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

NCT01865747
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib tablets, Everolimus (Afinitor) tablets
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

NCT03154281
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
niraparib, everolimus
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

NCT03355794
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma, Brainstem Glioma, Glioblastoma, Anaplastic Astrocytoma
Interventions
ribociclib, Everolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 30 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512
View directory record Official record
Conditions
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
Interventions
Everolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

NCT01419639
View directory record Official record
Conditions
Neurofibromatosis Type II
Interventions
Everolimus (RAD001) , Afinitor®
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 1 Interventional Results available

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT01088048
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
11
States / cities
Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 28, 2026, 4:30 PM EDT
Terminated Phase 1 Interventional Results available

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT01889420
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Combination therapy
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Sep 28, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Cutaneous T-cell Lymphoma

NCT01637090
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Everolimus
Drug
Lead sponsor
Adam Lerner
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 28, 2026, 4:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Everolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

NCT01289912
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
RAD001, Placebo
Drug
Lead sponsor
Mustafa Sahin
Other
Eligibility
6 Years to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 28, 2026, 4:30 PM EDT
Terminated Phase 2 Interventional Results available

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

NCT02560012
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sunitinib, Temsirolimus, Sorafenib, Pazopanib, Everolimus, Axitinib
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT01797523
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Metformin, Letrozole, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
6
States / cities
Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 28, 2026, 4:30 PM EDT
Terminated Phase 1 Interventional Results available

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

NCT01642732
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, lupron, bicalutamide, and radiation
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 4:30 PM EDT
Not listed Phase 2 Interventional

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

NCT01263951
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Everolimus, Sorafenib
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 89 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 28, 2026, 4:30 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

NCT07218575
View directory record Official record
Conditions
Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions
Everolimus blinded oral capsules, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 1 Interventional

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

NCT01596140
View directory record Official record
Conditions
Advanced Cancer, Solid Tumor
Interventions
Vemurafenib, Everolimus, Temsirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 28, 2026, 4:30 PM EDT
Completed Phase 2 Interventional Results available

Rapalogues for Autism Phenotype in TSC: A Feasibility Study

NCT01929642
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Self-injury, Autism
Interventions
Sirolimus, Everolimus
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
2 Years to 30 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 28, 2026, 4:30 PM EDT